Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04640038 · ClinicalTrials.gov registry record · Phase 3
Contrast Enhanced Ultrasound in COVID-19
A Phase 3 study of Covid19 and Multisystem Inflammatory Syndrome in Children (MIS-C), sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT04640038 is a Phase 3 study of Covid19 and Multisystem Inflammatory Syndrome in Children (MIS-C) that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 4 participants, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04640038, a Phase 3 study of Covid19 and Multisystem Inflammatory Syndrome in Children (MIS-C), has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
Initial data from COVID-19 patients suggests that one of the primary causes of death is significant endothelial injury leading to blood clotting and impaired multiorgan microvascular perfusion. The current study uses a safe, convenient bedside imaging tool called contrast-enhanced ultrasound (CEUS) to estimate the extent of microvascular perfusion impairment in the heart, kidneys and/or brain of COVID-19 pediatric patients in vivo and assess the significance of imaging findings by correlating to clinical outcomes. This pilot study will be conducted at one site, The Children's Hospital of Philadelphia. The investigators plan to enroll and evaluate 30 patients.
Conditions Studied
Interventions
- DRUG Sulfur hexafluoride lipid-type A microspheres
Study Locations (1)
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-12-18 |
| Est. Completion | 2021-09-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04640038
The ClinicalTrials.gov registry entry for NCT04640038 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (100% lower). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Covid19 appearing as the primary indexed condition, and to 1 intervention - of which Sulfur hexafluoride lipid-type A microspheres is the first listed.
NCT04640038 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04640038 about?
NCT04640038 is a clinical study titled "Contrast Enhanced Ultrasound in COVID-19". Initial data from COVID-19 patients suggests that one of the primary causes of death is significant endothelial injury leading to blood clotting and impaired multiorgan microvascular perfusion. The current study uses a safe, convenient bedside imaging tool called contrast-enhanced ultrasound (CEUS) ...
What is the current status of trial NCT04640038?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2020-12-18. Estimated completion is 2021-09-17.
What conditions does trial NCT04640038 study?
This clinical trial studies the following conditions: Covid19, Multisystem Inflammatory Syndrome in Children (MIS-C).
What interventions are being tested in trial NCT04640038?
The interventions under investigation include: Sulfur hexafluoride lipid-type A microspheres (DRUG).
Who is sponsoring clinical trial NCT04640038?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04640038 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
COMPLETED · Phase 3
-
Aggrenox To Treat Acute Covid-19
COMPLETED · Phase 3
-
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
COMPLETED · Phase 3
-
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
COMPLETED · Phase 3
Explore more on PlainTrial
Covid19
All registered trials for this condition
Multisystem Inflammatory Syndrome in Children (MIS-C)
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.